
As an Amazon Associate and affiliate partner, Menrva Books earns from qualifying purchases. Learn more
Nowhere is the explosion in comprehensive genomic testing more evident than in oncology. Multiple consensus guidelines now recommend molecular testing as the standard of care for most metastatic tumors. To aid in the advancement of this rapidly changing field, we intend this Special Issue of JPM to focus on technical developments in the genomic profiling of cancer, detail promising somatic alterations that either are, or have a high likelihood of being, relevant in the near future, and to address issues related to the pricing and value of these tests. The last few years have seen the cost of molecular testing decrease by orders of magnitude. In 2018, we saw the first "site-agnostic" drug approvals in cancer (for microsatellite unstable cancer (PD-1 inhibitors) and NTRK-fusions (TRK inhibitors)). Research on targetable mutations, determination of genetic "signatures" that can use multiple individual genes/pathways, development of targeted therapy, and insight into the value of new technology remains at the cutting edge of research in this field. We are soliciting papers that present new technologies to assess predictive biomarkers in cancer, original research (pre-clinical or clinical) that demonstrates promise for particular targeted therapies in cancer, and articles that explore the clinical and financial impacts of this paradigmatic shift in cancer diagnostics and treatment.
The rapid advancements in genomic testing are revolutionizing cancer treatment, necessitating a comprehensive understanding of new technologies and their clinical implications. This Special Issue of JPM delves into the technical developments in cancer genomic profiling, highlighting promising somatic alterations and addressing the economic value of these tests. It explores the impact of decreasing molecular testing costs, the rise of site-agnostic drug approvals, and ongoing research into targetable mutations and predictive biomarkers. The collection seeks original research and analyses on the clinical and financial shifts in cancer diagnostics and treatment.
This collection of papers addresses the cutting edge of oncology, focusing on the integration of genomic testing into standard care. The articles are expected to provide detailed insights into new technologies, promising therapeutic targets, and the economic considerations of advanced diagnostics. The compilation aims to inform researchers and clinicians about the evolving landscape of personalized cancer treatment.
Page Count:
190
Publication Date:
2022-01-25
Publisher:
MDPI AG
ISBN-10:
3036528210
ISBN-13:
9783036528212
No comments yet. Be the first to share your thoughts!